Discerning primary and secondary factors responsible for clinical fatigue in multisystem diseases

Biology

Volumn 3, Issue 3, 2014, Pages 606-622

  Maughan, David ^a   Toth, Michael ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Cancer; Chronic fatigue syndrome; Heart failure; Multi system diseases; Multiple sclerosis; Muscle deconditioning; Muscular fatigue

Indexed keywords

EID: 84907875443     PISSN: None     EISSN: 20797737     Source Type: Journal    
DOI: 10.3390/biology3030606     Document Type: Review

References (100)

1. Ferriolli, E.; Skipworth, R.J.E.; Hendry, P.; Scott, A.; Stensteth, J.; Dahele, M.; Wall, L.; Greig, C.; Fallon, M.; Strasser, F.; et al. Physical activity monitoring: A responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy? J. Pain Symptom Manag. 2012, 43, 1025-1035.
2. Toth, M.J.; Gottlieb, S.S.; Goran, M.I.; Fisher, M.L.; Poehlman, E.T. Daily energy expenditure in free-living heart failure patients. Am. J. Physiol. Endocrinol. Metab. 1997, 272, E469-E475.
3. Pitta, F.; Troosters, T.; Spruit, M.A.; Probst, V.S.; Decramer, M.; Gosselink, R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am. J. Respir Crit Care Med. 2005, 171, 972-977.
4. Edwards, R.H. Human muscle function and fatigue. Ciba Found. Symp. 1981, 82, 1-18.
5. Kent-Braun, J.A.; Fitts, R.H.; Christie, A. Skeletal muscle fatigue. Compr. Physiol. 2012, 2, 997-1044.
6. Carruthers, B.M.; van de Sande, M.I.; De Meirleir, K.L.; Klimas, N.G.; Broderick, G.; Mitchell, T.; Staines, D.; Powles, A.C.; Speight, N.; Vallings, R., et al. Myalgic encephalomyelitis: International Consensus Criteria. J. Intern. Med. 2011, 270, 327-338.
7. Holmes, G.P.; Kaplan, J.E.; Gantz, N.M.; Komaroff, A.L.; Schonberger, L.B.; Straus, S.E.; Jones, J.F.; Dubois, R.E.; Cunningham-Rundles, C.; Pahwa, S, et al. Chronic fatigue syndrome: A working case definition. Ann. Intern. Med. 1988, 108, 387-389.
8. Morris, G.; Maes, M. A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome. Metab. Brain Dis. 2013, 28, 523-540.
9. Morris, G.; Maes, M. Myalgic encephalomyelitis/chronic fatigue syndrome and encephalomyelitis disseminata/multiple sclerosis show remarkable levels of similarity in phenomenology and neuroimmune characteristics. BMC Med. 2013, 11, 205.
10. Bierl, C.; Nisenbaum, R.; Hoaglin, D.C.; Randall, B.; Jones, A.B.; Unger, E.R.; Reeves, W.C. Regional distribution of fatiguing illnesses in the United States: A pilot study. Popul. Health Metr. 2004, 2, 1.
11. Sommer, C.; Hauser, W.; Burgmer, M.; Engelhardt, R.; Gerhold, K.; Petzke, F.; Schmidt-Wilcke, T.; Spath, M.; Tolle, T.; Uceyler, N.; et al. Etiology and pathophysiology of fibromyalgia syndrome. Schmerz 2012, 26, 259-267.
12. Klimas, N.G.; Koneru, A.O. Chronic fatigue syndrome: Inflammation, immune function, and neuroendocrine interactions. Curr. Rheumatol. Rep. 2007, 9, 482-487.
13. Barnden, L.R.; Crouch, B.; Kwiatek, R.; Burnet, R.; Mernone, A.; Chryssidis, S.; Scroop, G.; Del Fante, P. A brain MRI study of chronic fatigue syndrome: Evidence of brainstem dysfunction and altered homeostasis. NMR Biomed. 2011, 24, 1302-1312.
14. Pall, M.L. Elevated, sustained peroxynitrite levels as the cause of chronic fatigue syndrome. Med. Hypotheses 2000, 54, 115-125.
15. Pall, M.L. Novel Disease Paradigm Produces Explanations for a Whole Group of Illnesses; Washington State University: Pullman, WA, USA, 2009.
16. Booth, N.E.; Myhill, S.; McLaren-Howard, J. Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Int. J. Clin. Exp. Med. 2012, 5, 208.
17. Myhill, S.; Booth, N.E.; McLaren-Howard, J. Targeting mitochondrial dysfunction in the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) - a clinical audit. Int. J. Clin. Exp. Med. 2013, 6, 1-15.
18. Morris, G.; Maes, M. Increased nuclear factor-kappaB and loss of p53 are key mechanisms in Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med. Hypotheses 2012, 79, 607-613.
19. Carlson, B.E.; Vigoreaux, J.O.; Maughan, D.W. Diffusion coefficients of endogenous cytosolic proteins from rabbit skinned muscle fibers. Biophys. J. 2014, 106, 780-792.
20. Massie, B.M.; Conway, M.; Rajagopalan, B.; Yonge, R.; Frostick, S.; Ledingham, J, Sleight, P, Radda, G. Skeletal muscle metabolism during exercise under ischemic conditions in congestive heart failure: Evidence for abnormalities unrelated to blood flow. Circulation 1988, 78, 320-326.
21. Newton, D.J.; Kennedy, G.; Chan, K.K.; Lang, C.C.; Belch, J.J.; Khan, F. Large and small artery endothelial dysfunction in chronic fatigue syndrome. Int. J. Cardiol. 2012, 154, 335-336.
22. Lemle, M.D. Hypothesis: Chronic fatigue syndrome is caused by dysregulation of hydrogen sulfide metabolism. Med. Hypotheses 2009, 72, 108-109.
23. Kobayashi, Y.M.; Rader, E.P.; Crawford, R.W.; Iyengar, N.K.; Thedens, D.R.; Faulkner, J.A.; Parikh, S.V.; Weiss, R.M.; Chamberlain, J.S.; Moore, S.A, et al. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 2008, 456, 511-515.
24. Lane, R.J.; Barrett, M.C.; Taylor, D.J.; Kemp, G.J.; Lodi, R. Heterogeneity in chronic fatigue syndrome: Evidence from magnetic resonance spectroscopy of muscle. Neuromuscul. Disord. 1998, 8, 204-209.
25. Wong, R.; Lopaschuk, G.; Zhu, G.; Walker, D.; Catellier, D.; Burton, D.; Teo, K.; Collins-Nakai, R.; Montague, T. Skeletal muscle metabolism in the chronic fatigue syndrome. In vivo assessment by 31P nuclear magnetic resonance spectroscopy. Chest 1992, 102, 1716-1722.
26. McCully, K.K.; Natelson, B.H.; Iotti, S.; Sisto, S.; Leigh, J.S., Jr. Reduced oxidative muscle metabolism in chronic fatigue syndrome. Muscle Nerve 1996, 19, 621-625.
27. Connolly S.; Smith, D.G.; Doyle, D.; Fowler, C.J. Chronic fatigue: Electromyographic and neruopathological evaluation. J. Neuro 1993, 240, 435-438.
28. Fulle, S.; Belia, S.; Vecchiet, J.; Morabito, C.; Vecchiet, L.; Fano, G. Modification of the functional capacity of sarcoplasmic reticulum membranes in patients suffering from chronic fatigue syndrome. Neuromuscul. Disord. 2003, 13, 479-484.
29. Light, A.R.; Bateman, L.; Jo, D.; Hughen, R.W.; Vanhaitsma, T.A.; White, A.T.; Light, K.C. Gene expression alterations at baseline and following moderate exercise in patients with Chronic Fatigue Syndrome and Fibromyalgia Syndrome. J. Intern. Med. 2012, 271, 64-81.
30. Light, A.R.; White, A.T.; Hughen, R.W.; Light, K.C. Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. J. Pain 2009, 10, 1099-1112.
31. Pall, M.L. Chronic fatigue syndrome/myalgic encephalitis. Br. J. Gen. Pract. 2002, 52, 762; author reply 763-764.
32. Shor, S. Pathogenesis of Chronic Fatigue Syndrome, a Multisystem Hypothesis. J. Chronic Fatigue Syndr. 2003, 11, 51-68.
33. McCully, K.K.; Natelson, B.H. Impaired oxygen delivery to muscle in chronic fatigue syndrome. Clin. Sci. (Lond) 1999, 97, 603-608; discussion 611-613.
34. McCully, K.K.; Smith, S.; Rajaei, S.; Leigh, J.S., Jr.; Natelson, B.H. Muscle metabolism with blood flow restriction in chronic fatigue syndrome. J. Appl. Physiol. (1985) 2004, 96, 871-878.
35. VanNess, J.M.; Snell, C.R.; Stevens, S.R. Diminished Cardiopulmonary Capacity during Post-Exertional Malaise. J. Chronic Dis. Syndr. 2007, 14, 77-85.
36. Carruthers, B.M.; van de Sande, M…I.; De Meirleir, K.L.; Klimas, N.G.; Broderick, G.; Mitchell, T.; Staines, D.; Powles, A.C.; Speight, N.; Vallings, R, et al. Myalgic Encephalohyeltitis—Adult & Paediatric: International Concensus Primer for Medical Practitioners; Carruthers & van de Sande: Vancouver, BC, Canada, 2012.
37. LaManca, J.J.; Sisto, S.A.; DeLuca, J.; Johnson, S.K.; Lange, G.; Pareja, J.; Cook, S.; Natelson, B.H. Influence of exhaustive treadmill exercise on cognitive functioning in chronic fatigue syndrome. Am. J. Med. 1998, 105, 59S-65S.
38. Blackwood, S.K.; MacHale, S.M.; Power, M.J.; Goodwin, G.M.; Lawrie, S.M. Effects of exercise on cognitive and motor function in chronic fatigue syndrome and depression. J. Neurol. Neurosurg. Psychiatry 1998, 65, 541-546.
39. Cook, D.B.; Nagelkirk, P.R.; Peckerman, A.; Poluri, A.; Mores, J.; Natelson, B.H. Exercise and cognitive performance in chronic fatigue syndrome. Med. Sci. Sports Exerc. 2005, 37, 1460-1467.
40. Yoshiuchi, K.; Cook, D.B.; Ohashi, K.; Kumano, H.; Kuboki, T.; Yamamoto, Y.; Natelson, B.H. A real-time assessment of the effect of exercise in chronic fatigue syndrome. Physiol. Behav. 2007, 92, 963-968.
41. VanNess, J.M.; Stevens, S.R.; Bateman, L.; Stiles, T.L.; Snell, C.R. Postexertional malaise in women with chronic fatigue syndrome. J. Womens Health (Larchmt) 2010, 19, 239-244.
42. Gonsette, R.E. Neurodegeneration in multiple sclerosis: The role of oxidative stress and excitotoxicity. J. Neurol. Sci. 2008, 274, 48-53.
43. van Horssen, J.; Schreibelt, G.; Drexhage, J.; Hazes, T.; Dijkstra, C.D.; van der Valk, P.; de Vries, H.E. Severe oxidative damage in multiple sclerosis lesions coincides with enhanced antioxidant enzyme expression. Free Radic. Biol. Med. 2008, 45, 1729-1737.
44. Lu, F.; Selak, M.; O'Connor, J.; Croul, S.; Lorenzana, C.; Butunoi, C.; Kalman, B. Oxidative damage to mitochondrial DNA and activity of mitochondrial enzymes in chronic active lesions of multiple sclerosis. J. Neurol. Sci. 2000, 177, 95-103.
45. Mahad, DJ, Ziabreva, I, Campbell, G, Lax, N, White, K, Hanson, P.S, Lassmann, H, Turnbull, D.M. Mitochondrial changes within axons in multiple sclerosis. Brain 2009, 132, 1161-1174.
46. Higgins, G.C.; Beart, P.M.; Shin, Y.S.; Chen, M.J.; Cheung, N.S.; Nagley, P. Oxidative stress: Emerging mitochondrial and cellular themes and variations in neuronal injury. J. Alzheimers Dis. 2010, 20, S453-S473.
47. Adhya, S.; Johnson, G.; Herbert, J.; Jaggi, H.; Babb, J.S.; Grossman, R.I.; Inglese, M. Pattern of hemodynamic impairment in multiple sclerosis: Dynamic susceptibility contrast perfusion MR imaging at 3.0 T. Neuroimage 2006, 33, 1029-1035.
48. Brooks, D.J.; Leenders, K.L.; Head, G.; Marshall, J.; Legg, N.J.; Jones, T. Studies on regional cerebral oxygen utilisation and cognitive function in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 1984, 47, 1182-1191.
49. Rashid, W.; Parkes, L.M.; Ingle, G.T.; Chard, D.T.; Toosy, A.T.; Altmann, D.R.; Symms, M.R.; Tofts, P.S.; Thompson, A.J.; Miller, D.H. Abnormalities of cerebral perfusion in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 2004, 75, 1288-1293.
50. Debouverie, M.; Pittion, S. Fatigue and episodic exhaustion as a feature of multiple sclerosis. Rev. Neurol. (Paris) 2006, 162, 295-297.
51. Lenman, A.J.; Tulley, F.M.; Vrbova, G.; Dimitrijevic, M.R.; Towle, J.A. Muscle fatigue in some neurological disorders. Muscle Nerve 1989, 12, 938-942.
52. Sharma, K.R.; Kent-Braun, J.; Mynhier, M.A.; Weiner, M.W.; Miller, R.G. Evidence of an abnormal intramuscular component of fatigue in multiple sclerosis. Muscle Nerve 1995, 18, 1403-1411.
53. Petajan, J.H.; White, A.T. Motor-evoked potentials in response to fatiguing grip exercise in multiple sclerosis patients. Clin. Neurophysiol. 2000, 111, 2188-2195.
54. Ng, A.V.; Miller, R.G.; Gelinas, D.; Kent-Braun, J.A. Functional relationships of central and peripheral muscle alterations in multiple sclerosis. Muscle Nerve 2004, 29, 843-852.
55. McArdle, W.D.; Katch, F.I.; Katch, V.L. Excercise Physiology, 7th ed.; Wolters Kluwer/Lippincott Williams & Wilkins Health: Philadelphia, PA, USA, 2010.
56. Ng, A.V.; Kent-Braun, J.A. Quantitation of lower physical activity in persons with multiple sclerosis. Med. Sci. Sports Exerc. 1997, 29, 517-523.
57. Vogelzang, N.J.; Breibart, W.; Cella, D.; Curt, G.A.; Groopman, J.E.; Horning, S.J.; Itri, L.M.; Johnson, D.H.; Scherr, S.L.; Portenoy, R.K. Patient, caregiver, and oncologist perceptions of cancer-related fatigue: Results of a tripart assessment survey. The Fatigue Coalition. Semin. Hematol. 1997, 34, 4-12.
58. Butt, Z.; Rosenbloom, S.K.; Abernethy, A.P.; Beaumont, J.L.; Paul, D.; Hamptom, D.; Jacobsen, P.B.; Syrjala, K.L.; Von Roenn, J.H.; Cella, D. Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J. Natl. Compr. Cancer Netw. 2008, 6, 448-455.
59. Cella, D.; Davis, K.; Breitbart, W.; Curt, G.; Fatigue Coalition. Cancer-related fatigue:Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J. Clin. Oncol. 2001, 19, 3385-3391.
60. Braithwaite, D.; Satariano, W.A.; Sternfeld, B.; Hiatt, R.A.; Ganz, P.A.; Kerlikowske, K.; Moore, D.H.; Slattery, M.L.; Tammemagi, M.; Castillo, A, et al. Long-term prognostic role of functional limitations among women with breast cancer. J. Natl. Compr. Cancer Netw. 2010, 102, 1468-1477.
61. Brunelli, A.; Pompili, C.; Berardi, R.; Mazzanti, P.; Onofri, A.; Salati, M.; Cascinu, S.; Sabbatini, A. Performance at preoperative stair-climbing test is associated with prognosis after pulmonary resection in Stage I non-small cell lung cancers. Ann. Thorac. Surg. 2012, 93, 1796-1800.
62. Jones, L.W.; Hornsby, W.E.; Goetzinger, A.; Forbes, L.M.; Sherrard, E.L.; Quist, M.; Lane, A.T.; West, M.; Eves, N.D.; Gradison, M, et al. Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. Lung Cancer 2012, 76, 248-252.
63. Miller, K.L.; Kocak, Z.; Kahn, D.; Zhou, S.-M.; Baydush, A.; Hollis, D.; Folz, R.J.; Tisch, A.; Clough, R.; Yu, X, et al. Preliminary report of the 6-minute walk test as a predictor of radiation-induced pulmonary toxicity. Int. J. Radiat. Oncol. Biol. Phys. 2005, 62, 1009-1013.
64. Jatoi, A.; Hillman, S.; Stella, P.; Mailliard, J.; Sloan, J.; Vanone, S.; Cannon, M.; Kutteh, L.; Kanard, A.; Jett, J. Daily activities: Exploring their spectrum and prognostic impact in older, chemotherapy-treated lung cancer patients. Support. Care Cancer 2003, 11, 460-464.
65. Fearon, K.C.; Glass, D.J.; Guttridge, D.C. Cancer cachexia: Mediators, signaling, and metabolic pathways. Cell Metab. 2012, 16, 153-166.
66. Toth, M.J.; Miller, M.S.; Callahan, D.M.; Sweeny, A.P.; Nunez, I.; Grunberg, S.M.; Der-Torossian, H.; Couch, M.E.; Dittus, K. Molecular mechanisms underlying skeletal muscle weakness in human cancer: Reduced myosin-actin cross-bridge formation and kinetics. J. Appl. Physiol. 2013, 114, 858-868.
67. Acharyya, S.; Ladner, K.J.; Nelsen, L.L.; Damrauer, J.; Reiser, P.J.; Swoap, S.; Guttridge, D.C. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J. Clin. Invest. 2004, 114, 370-378.
68. Eley, H.L.; Skipworth, R.J.E.; Deans, D.A.C.; Fearon, K.C.H.; Tisdale, M.J. Increased expression of phosphorylated forms of RNA-dependent protein kinase and eukaryotic initiation factor 2[alpha] may signal skeletal muscle atrophy in weight-losing cancer patients. Br. J. Cancer 2007, 98, 443-449.
69. Cosper, P.F.; Leinwand, L.A. Myosin heavy chain is not selectively decreased in murine cancer cachexia. Int. J. Cancer 2012, 130, 2722-2727.
70. Weber, M.-A.; Krakowski-Roosen, H.; Schröder, L.; Kinscherf, R.; Krix, M.; Kopp-Schneider, A.; Essig, M.; Bachert, P.; Kauczor, H.-U.; Hildebrandt, W. Morphology, metabolism, microcirculation, and strength of skeletal muscles in cancer-related cachexia. Acta Oncol. 2009, 48, 116-124.
71. Stephens, N.A.; Gray, C.; MacDonald, A.J.; Tan, B.H.; Gallagher, I.J.; Skipworth, R.J.E.; Ross, J.A.; Fearon, K.C.H.; Greig, C.A. Sexual dimorphism modulates the impact of cancer cachexia on lower limb muscle mass and function. Clin. Nutr. 2012, 31, 499-505.
72. Aulino, P.; Berardi, E.; Cardillo, V.; Rizzuto, E.; Perniconi, B.; Ramina, C.; Padula, F.; Spugnini, E.; Baldi, A.; Faiola, F, et al. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer 2010, 10, 363.
73. Murphy, K.T.; Chee, A.; Trieu, J.; Naim, T.; Lynch, G.S. Importance of functional and metabolic impairments in the characterization of the C-26 murine model of cancer cachexia. Dis. Model. Mech. 2012, 5, 533-545.
74. Toledo, M.; Busquets, S.; Sirisi, S.; Serpe, R.; Orpi, M.; Coutinho, J.; Martinez, R.; Lopez-Soriano, F.J.; Argiles, J.M. Cancer cachexia: Physical activity and muscle force in tumor bearing rats. Oncol. Rep. 2011, 25, 183-193.
75. Der-Torossian, H.; Couch, M.E.; Dittus, K.; Toth, M.J. Skeletal muscle adaptations to cancer and its treatment: Their fundamental basis and contribution to functional disability. Crit. Rev. Eukaryot. Gene Expr. 2013, 23, 283-297.
76. Julienne, C.; Dumas, J.-.F.; Goupille, C.; Pinault, M.; Berri, C.; Collin, A.; Tesseraud, S.; Couet, C.; Servais, S. Cancer cachexia is associated with a decrease in skeletal muscle mitochondrial oxidative capacities without alteration of ATP production efficiency. J. Cachexia Sarcopenia Muscle 2012, 3, 265-275.
77. Tzika, A.A.; Fontes-Oliveria, C.C.; Shestova, A.A.; Constantinou, C.; Psychogios, N.; Righi, V, Mintzopoulos, D, Busquets, S, Lopez-Soriano, F.J, Milote, S, et al. Skeletal muscle mitochondrial uncoupling in a murine cancer cachexia model. Int. J. Oncol. 2013, 43, 886-894.
78. Gilliam, L.A.A.; Fisher-Wellman, K.H.; Lin, C.-T.; Maples, J.M.; Cathey, B.L.; Neufer, P.D. The anticancer agent doxorubicin disrupts mitochondrial energy metabolism and redox balance in skeletal muscle. Free Radic. Biol. Med. 2013, 65, 988-996.
79. Pinto, B.M.; Trunzo, J.J.; Reiss, P.; Shiu, S.Y. Exercise participation after diagnosis of breast cancer: Trends and effects on mood and quality of life. Psychooncology 2002, 11, 389-400.
80. Courneya, K.S.; McKenzie, D.C.; Mackey, J.R.; Gelmon, K.; Friedenreich, C.M.; Yasui, Y.; Reid, R.D.; Cook, D.; Jespersen, D.; Proulx, C, et al. Effects of Exercise Dose and Type during Breast Cancer Chemotherapy: Multicenter Randomized Trial. J. Natl. Cancer Inst. 2013, 105, 1821-1832.
81. Jones, L.W.; Alfano, C.M. Exercise-oncology research: Past, present, and future. Acta Oncol. 2013, 52, 195-215.
82. Coats, A.J.S. The “muscle hypothesis” of chronic heart failure. J. Mol. Cell. Cardiol. 1996, 28, 2255-2262.
83. Zizola, C.; Schulze, P.C. Metabolic and structural impairment of skeletal muscle in heart failure. Heart Fail. Rev. 2013, 18, 623-630.
84. Mancini, D.M.; Coyle, E.; Coggan, A.; Beltz, J.; Ferraro, N.; Montain, S.; Wilson, J.R. Contribution of intrinsic skeletal muscle changes to 31P-NMR skeletal muscle metabolic abnormalities in patients with chronic heart failure. Circulation 1989, 80, 1338-1346.
85. Sullivan, M.J.; Green, H.J.; Cobb, F.R. Skeletal muscle biochemistry and histology in ambulatory patients with long-term heart failure. Circulation 1990, 81, 518-527.
86. Callahan, D.M.; Toth, M.J. Skeletal muscle protein metabolism in human heart failure. Curr. Opin. Clin. Nutr. Metab. Care 2013, 16, 66-71.
87. Harrington, D.; Anker, S.; Chua, T.P.; Webb-Peploe, K.M.; Ponikowski, P.P.; Poole-Wilson, P.A.; Coats, A.J.S. Skeletal muscle function and its relation to exercise tolerance in chronic heart failure. J. Am. Coll. Cardiol. 1997, 30, 1758-1764.
88. Vescovo, G.; Serafini, F.; Facchin, L.; Tenderini, P.; Carraro, U.; Dalla Libera, L.; Catani, C.; Ambrosio, G.B. Specific changes in skeletal muscle myosin heavy chain composition in cardiac failure: Differences compared with disuse atrophy as assessed on microbiopsies by high resolution electrophoresis. Heart 1996, 76, 337-343.
89. Drexler, H.; Riede, U.; Munzel, T.; Konig, H.; Funke, E.; Just, H. Alterations in skeletal muscle in chronic heart failure. Circulation 1992, 85, 1751-1759.
90. Minotti, J.R.; Pillay, P.; Chang, L.; Wells, L.; Massie, B.M. Neurophysiological assessment of skeletal muscle fatigue in patients with congestive heart failure. Circulation 1992, 86, 903-908.
91. Miller, M.S.; VanBuren, P.; LeWinter, M.M.; Braddock, J.M.; Ades, P.A.; Maughan, D.W.; Palmer, B.M.; Toth, M.J. Chronic heart failure decreases cross-bridge kinetics in single skeletal muscle fibres from humans. J. Physiol. 2010, 588, 4039-4053.
92. Miller, M.S.; VanBuren, P.; LeWinter, M.M.; Lecker, S.H.; Selby, D.E.; Palmer, B.M.; Maughan, D.W.; Ades, P.A.; Toth, M.J. Mechanisms underlying skeletal muscle weakness in human heart failure: Alterations in single fiber myosin protein content and function. Circ. Heart Fail. 2009, 2, 700-706.
93. Rehn, T.A.; Munkvik, M.; Lunde, P.K.; Sjaastad, I.; Sejersted, O.M. Intrinsic skeletal muscle alterations in chronic heart failure patients: A disease-specific myopathy or a result of deconditioning? Heart Fail. Rev. 2012, 17, 421-436.
94. Mettauer, B.; Zoll, J.; Sanchez, H.; Lampert, E.; Ribera, F.; Veksler, V.; Bigard, X.; Mateo, P.; Epailly, E.; Lonsdorfer, J, et al. Oxidative capacity of skeletal muscle in heart failure patients versus sedentary or active controls subjects. J. Am. Coll. Cardiol. 2001, 38, 947-954.
95. Chati, Z.; Zannad, F.; Jeandel, C.; Lherbier, B.; Escanye, J.-M.; Robert, J.; Aliot, E. Physical deconditioning may be a mechanism for the skeletal muscle energy phosphate metabolism abnormalities in chronic heart failure. Am. Heart J. 1996, 131, 560-566.
96. Williams, A.D.; Selig, S.; Hare, D.L.; Hayes, A.; Krum, H.; Patterson, J.; Geerling, R.H.; Toia, D.; Carey, M.F. Reduced exercise tolerance in CHF may be related to factors other than impaired skeletal muscle oxidative capacity. J. Card Fail. 2004, 10, 141-148.
97. Toth, M.J.; Shaw, A.O.; Miller, M.S.; VanBuren, P.; LeWinter, M.M.; Maughan, D.; Ades, P.A. Reduced knee extensor function in heart failure is not explained by inactivity. Int. J. Cardiol. 2010, 143, 276-282.
98. Pollak, K.A.; Swenson, J.D.; Vanhaitsma, T.A.; Hughen, R.W.; Jo, D.; Light, K.C, Schweinhardt, P, Amann, M, Light, A.R. Exogenously applied muscle metabolites synergistically evoke sensations of muscle fatigue and pain in human subjects. Exp. Physiol. 2014, 99, 368-380.
99. White, P.D.; Goldsmith, K.A.; Johnson, A.L.; Potts, L.; Walwyn, R.; DeCesare, J.C.; Baber, H.L.; Burgess, M.; Clark, L.V.; Cox, D.L, et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): A randomised trial. Lancet 2011, 377, 823-836.
100. Twisk, F.N.; Maes, M. A review on cognitive behavorial therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. Neuro Endocrinol. Lett. 2009, 30, 284-299.